The FDA has approved Azor (amlodipine/olmesartan medoxomil tablets, from Daiichi Sankyo), a combination product containing a calcium channel blocker and an angiotensin II receptor blocker, as first-line therapy in patients likely to need multiple antihypertensive agents to help control their blood pressure.  This approval was based on data from the pivotal registration trial, which provided estimates of the probability of patients attaining blood pressure goals with Azor compared to amlodipine or olmesartan medoxomil alone.

For more information call (877) 437-7763 or visit